## LJI Available Technologies



## Anti-SARS-CoV-2 Nucleoprotein **Antibodies**

Researchers at the La Jolla Institute for Immunology have isolated and sequenced mouse plasma cells that produce antibodies targeting the nucleoprotein of SARS-CoV-2. These antibodies may be useful in saliva-based diagnostic tests or as basic research tools. They may also be useful for the design of therapeutics for the prevention or treatment of SARS-CoV-2.

The worldwide spread of SARS-CoV-2 in the human population has resulted in the ongoing COVID-19 pandemic and has already caused more than 491 million infections and more than 6.2 million deaths resulting from SARS-CoV-2 or related diseases and conditions. As such, effective countermeasures against the emergence and expansion of SARS-CoV-2 are required. Such effective countermeasures include the development of new tools for detection, diagnosis, monitoring, and treatment.


As such, researchers at LJI have isolated and sequenced SARS-CoV-2 antibodies from mouse plasma cells. These antibodies specifically target the nucleoprotein of SARS-CoV-2, and they may be useful in diagnostic tests, as basic research tools, or for the design of therapeutics that prevent and/or treat COVID-19 disease.

Tech ID # 2020-125

## **ADVANTAGES:**

- Useful for in saliva-based diagnostic tests
- Useful as basic research tools
- Useful for the design of therapeutics for the prevention/treatment of SARS-CoV-2

Anti-SARS-CoV-2 Nucleoprotein Antibodies Isolated from Mouse Plasma Cells



ELISA binding data showing the on/off the N antibodies